打开APP

百健艾迪与爱丁堡大学达成神经退行性疾病研发合作

  1. 多发性硬化症
  2. 爱丁堡大学
  3. 百健艾迪
  4. 神经退行性疾病

来源:生物谷 2013-07-24 09:28

2013年7月23日讯 /生物谷BIOON/ --百健艾迪(Biogen Idec)和爱丁堡大学(University of Edinburgh)于7月19日达成了一项为期3年的合作,研究多发性硬化症(MS)和运动神经元疾病,然后鉴定出可能用于治疗疾病的药物和化合物。

2013年7月23日讯 /生物谷BIOON/ --百健艾迪(Biogen Idec)和爱丁堡大学(University of Edinburgh)于7月19日达成了一项为期3年的合作,研究多发性硬化症(MS)和运动神经元疾病,然后鉴定出可能用于治疗疾病的药物和化合物。此次合作旨在将百健艾迪的药物开发和开发等专业知识与爱丁堡大学在转化医学、神经科学、干细胞研究、再生医学方面的专业技术诀窍(know-how)结合起来。(生物谷Bioon.com)

英文原文:Biogen Idec, University of Edinburgh Team Up for Neurodegenerative Disease R&D

Jul 19, 2013 Biogen Idec and the University of Edinburgh have agreed to a three-year collaboration in which they plan to study multiple sclerosis (MS) and motor neuron disease, then identify drug compounds that could potentially be used as treatments.

The company will fund the collaboration, both partners said in a statement, though the amount of funding was undisclosed. The collaboration is designed to marry the biotech giant’s drug discovery and development expertise with the university’s know-how in translational medicine, as well as in neuroscience, stem cell research, and regeneration.

Biogen Idec markets several MS drugs, including Tysabri? (natalizumab), indicated for relapsing forms of MS in the U.S. and relapsing-remitting MS in the EU; and Avonex?, a drug indicated for relapsing forms of MS to slow its progression of disability and reduce relapses. Avonex is also approved for patients who have their first clinical MS attack and have brain MRI scans consistent with those of MS.

Biogen Idec also has a license from Acorda Therapeutics to develop and commercialize outside the U.S. Fampyra? (prolonged-release fampridine tablets), for improving walking in adult MS patients with walking disabilities.

The collaboration will join Biogen Idec’s investigators with researchers and clinicians based at Edinburgh BioQuarter, Scotland’s anchor biopharma campus, which includes the university. The BioQuarter is already the site of university research collaborations with other drug developers, including a deal with Galapagos to test new drug compounds; a partnership of at least two years with Galecto Biotech to develop the company’s Galectin-3 inhibitors as a treatment for fibrosis; and an effort with GlaxoSmithKline (GSK)’s Discovery Partnerships with Academia team to develop treatments for acute pancreatitis.

In the GSK deal, the university receives potential payments from GSK tied to research milestones, and royalties on sales from any product successfully commercialized through the collaboration.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->